Cost-Effectiveness Analysis of Aztreonam–Avibactam Compared with Colistin Plus Meropenem in Treating Metallo-Beta-Lactamase-Producing Enterobacterales Infections in Spain | Synapse

⌘+K

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Cost-Effectiveness Analysis of Aztreonam-Avibactam (ATM-AVI) Versus Colistin + Meropenem (COL + MER) for the Treatment of Infections Caused by Metallo-β-Lactamase (MBL)-Producing Enterobacterales in Italy2025 · 7 citations
2Aztreonam–Avibactam (Emblaveo®) for Carbapenem-Resistant and Metallo-β-Lactamase-Producing Gram-Negative Infections: A Comprehensive ReviewLate-Phase Clinical Trial · 2026
3A Comparative Evaluation of Aztreonam-Avibactam and Ceftazidime-Avibactam Plus Aztreonam for Infections Due to MBL-Producing EnterobacteralesOriginal Research · 2026 · 7 citations
4IN VITRO ACTIVITY OF AZTREONAM-AVIBACTAM AGAINST CLINICAL ISOLATES OF ENTEROBACTERALES COLLECTED IN BRAZIL FOR THE ATLAS SURVEILLANCE PROGRAM, 2018–2023Original Research · 2026
5Aztreonam and avibactam combination therapy for metallo-β-lactamase-producing gram-negative bacteria: A Narrative ReviewNarrative Review · 2024 · 55 citations
6The Combination of Aztreonam-Avibactam in Multidrug-Resistant Gram-Negative Infections2025 · 2 citations
7On the Optimal Treatment of Metallo-Beta-Lactamase–Producing Enterobacterales Infections Using Aztreonam and AvibactamEarly-Phase Clinical Trial · 2025 · 4 citations
8Aztreonam–Avibactam for Patients Who are Critically Ill with Gram-Negative Bacterial Infections: Comparison with Colistin Plus Meropenem Subgroup from the Phase 3 REVISIT StudyLate-Phase Clinical Trial · 2026
9Intensive Pharmaceutical versus Routine Care on Antifungal Drug Therapy Safety in Adult Hematology–Oncology Patients: A Prospective Multicenter Pre–Post Study (MAAMy)Infectious Diseases and Therapy · 2026
10Efficacy of Nirmatrelvir/Ritonavir in High-Risk Adults with Preexisting SARS-CoV-2 Immunity: A Pooled Analysis of Two Randomized Controlled TrialsInfectious Diseases and Therapy · 2026

More from Infectious Diseases and Therapy

More from Instituto de Salud Carlos III